Table 1 Baseline characteristics of the enrolled patients
Variable | HCC group (n = 41) | LC group (n = 55) | CHB group (n = 97) | HC group (n = 14) |
|---|---|---|---|---|
Sex (male/female) | 35/6 | 40/15 | 72/25 | 10/4 |
Age (years) | 60 (52.7–64.2) | 51 (41–59) | 41 (29.5–48.5) | 45 (32.7–49.7) |
HBeAg(−/+) | 24/17 | 28/27 | 34/63 | NA |
HBVDNA(−/+) | 19/22 | 17/38 | 19/78 | NA |
HBsAg | 4879 (2490–6796) | 4781 (2515–6819) | 3769 (1264–5728.5) | NA |
ALT (U/L) | 51 (32.7–99.3) | 42 (26–89) | 118 (43–272.5) | 17.5 (12–25.2) |
AST (U/L) | 86 (49–178.5) | 57 (39–85) | 56 (33–134) | 13.5 (12–17.2) |
TBIL (umol/L) | 24.9 (14.8–50.9) | 30.4 (18.7–60.2) | 18.5 (11.6–46.25) | 11 (8.7–13.2) |
ALB (g/L) | 35.8 (32.8–39.9) | 32.7 (29.1–38.1) | 41.3 (37.4–44.5) | 45 (44.5–54) |
PTA (%) | 75 (66–80.3) | 68 (55–80) | 94 (86–103) | 84.5 (79.5–90.5 |
AFP (ng/ml) | 444.5 (254.5–1693.5) | 25.8 (58.9–181.27) | 181.2 (8.2–118.3) | 12 (96.6–13) |
WBC (E+ 09/L) | 5.5 (3.9–9.6) | 5.8 (3.3–6.7) | 5.3 (4.6–6.4) | 5.8 (5.3–7.0) |
HGB (g/L) | 129 (110–143.5) | 129 (101–140) | 150 (140.5–155) | 141.5 (137.9–146) |
PLT (E+ 09/L) | 134 (98.7–211.3) | 98 (78–154) | 188 (154.3–229.5) | 193 (172.5–206) |